Celgene’s Rumored Juno Talks, Hospitals Shoot at Generic Drugmakers, & Keytruda Hits a Phase III

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.